Latest News
Conference Coverage
Duke’s Criteria help guide echocardiography decision in suspected infective endocarditis
A large number of echocardiograms ordered to detect infective endocarditis prompted investigators to look at appropriateness of this test.
Conference Coverage
EVAR registry results show equivalence between the sexes
EVAR outcomes between the sexes were equivalent at 30 days and 1 through 5 years.
Latest News
Doctors testify on health insurance stabilization
Support for innovation waivers and low cost, catastrophic plans high on list of reforms.
Conference Coverage
Alirocumab’s ODYSSEY continues: Efficacy unaffected by insulin, beats fenofibrate
LISBON – Lipids in either type of diabetes may have met their match.
Conference Coverage
VIDEO: What’s new in AAP’s pediatric hypertension guidelines
SAN FRANCISCO – Some of the advice is similar to the group’s last effort in 2004, but there are a few key changes.
From the Journals
Patent foramen ovale closure reduces risk of stroke in three trials
Risks of procedure must be weighed against the benefit of reduced stroke risk.
From the Journals
New data prompt update to ACC guidance on nonstatin LDL lowering
The ACC has updated its advice regarding the use of nonstatin therapies following clinical trial results of PCSK9 inhibitors and ezetimibe.
From the Journals
No increased overall cardiovascular risk seen with exenatide use
Patients with type 2 diabetes who took once-daily exenatide did not appear to have an increase in their overall cardiovascular risk, compared with...
Feature
FDA moves to guard against abuse of ‘orphan drug’ program
Of about 450 drugs that have won orphan approval since 1983, more than 70 were first approved by the FDA for mass-market use.
Conference Coverage
BIMA’s benefits extend to high-risk CABG patients
Is BIMA actually a surrogate marker for a highly skilled subspecialist who would be expected to have very good outcomes as a matter of course?
From the Journals
Postpartum NSAIDs didn’t up hypertension risk in preeclampsia
An adequately powered trial is still needed to settle the question of the safety of NSAIDs for women with preeclampsia.